Ruxolitinib Benefits Some Patients with Graft-Versus-Host Disease - Cancer Currents Blog National Cancer Institute sent this bulletin at 06/01/2020 12:12 PM EDT Having trouble viewing this email? View it as a Web page. You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below. More Evidence that Ruxolitinib Benefits Some Patients with Graft-Versus-Host Disease 05/29/2020 Patients with acute graft-versus-host disease (GVHD) that does not respond to steroid therapy are more likely to respond to the drug ruxolitinib (Jakafi) than other available treatments, results from a large clinical trial show.